ANN ARBOR, Mich., Jan. 15, 2019 (GLOBE NEWSWIRE) -- Zomedica Pharmaceuticals Corp. (NYSE American: ZOM) (TSX-V: ZOM), a veterinary diagnostic and pharmaceutical company, today announced the appointment of Bonnie Bragdon, DVM, MS, as Vice President of Veterinary Affairs. In this new company position, she will lead the veterinary medical strategy as it relates to industry trends, strategic partnerships, marketing, education and training to support Zomedica’s commercial product strategy, reporting to Chief Commercial Officer Bruk Herbst.
“I am pleased to welcome Dr. Bragdon to the Zomedica Team. Adding another experienced and well-respected clinical veterinarian to our ranks with her extensive industry background provides deep insight into customer needs and overcoming barriers to market entry and product adoption to help veterinarians improve the standard of care for companion animals,” stated Gerald Solensky Jr., Chief Executive Officer at Zomedica.
Dr. Bragdon joins Zomedica with 20 years of combined animal health leadership experience in clinical veterinary practice and operations, medical device and pharmaceutical development, marketing strategy and sales support, along with industry advocacy.
Most recently, Dr. Bragdon strategized and delivered continuing education to companion animal practitioners on medical and clinical operations as Technical Services Manager for Merck Animal Health, the global animal health business unit of Merck that offers veterinary pharmaceuticals, vaccines and health management solutions. Prior to that, Dr. Bragdon was the Senior Marketing Manager for BonVet Animal Health and spent more than six years in progressive positions with Abbott Animal Health including Senior Manager of New Products Scientific Assessment and Veterinary Liaison Manager before the company was acquired by Zoetis in 2015.
Dr. Bragdon started her career as a practicing veterinarian, serving for nearly 10 years as associate veterinarian, owner-veterinarian and director with various animal hospitals and county animal control in the state of Georgia, where she excelled in operations management alongside her responsibilities as a clinical practitioner. Dr. Bragdon received her doctor of veterinary medicine and Master of Veterinary Clinical Sciences from The Ohio State University. She is a member of the American Veterinary Medical Association (AVMA), the American Association of Industry Veterinarians (AAIV), and is a founding member of the Independent Veterinary Practitioner Association (IVPA). She currently serves as president of IVPA and represents AAIV in the AVMA’s House of Delegates. Dr. Bragdon strives to elevate the role of veterinarians in industry and business through her work in organized medicine.
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) (TSX-V: ZOM) is a veterinary diagnostic and pharmaceutical company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. Zomedica’s product portfolio will include novel diagnostics and innovative therapeutics that emphasize patient health and practice health. With a team that includes clinical veterinary professionals, it is Zomedica’s mission to give veterinarians the opportunity to lower costs, increase productivity, and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.
Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and pilot and pivotal studies, uncertainty as to the likelihood and timing of regulatory approvals, availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to future clinical trials, regulatory approvals, safety and efficacy of our products, the use of our product, intellectual property protection and the other risk factors disclosed in our filings with the Securities and Exchange Commission and under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contacts
Shameze Rampertab, CPA, CA
PCG Advisory Group
Kirin Smith, COO
Zomedica Pharmaceuticals Corp.